Comparison of Latanoprost and Timolol in Patients with Ocular Hypertension and Glaucoma: A Six-month, Masked, Multicenter Trial in the United States
References (35)
- et al.
Maintained reduction of intraocular pressure by prostaglandin F2α 1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients
Ophthalmology
(1989) - et al.
Effects of PhXA41, a new prostaglandin F2α analog, on aqueous humor dynamics in human eyes
Ophthalmology
(1993) - et al.
Intraocular pressure-reducing effects of PhXA41 in patients with increased eye pressure. A one-month study
Ophthalmology
(1993) - et al.
Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens
Ophthalmology
(1993) - et al.
Additivity of prostaglandin F2α 1-isopropyl ester to timolol in glaucoma patients
Ophthalmology
(1991) - et al.
Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders
Am J Ophthalmol
(1994) Prostaglandins
The potential of prostaglandin derivatives in glaucoma therapy
Curr Opin Ophthalmol
(1993)- et al.
Topical prostaglandin E2 effects on normal human intraocular pressure
J Ocul Pharmacol
(1988) - et al.
Prostaglandin FF2α-isopropylester eye drops: effects in normal human eyes
Br J Ophthalmol
(1989)
Prostaglandin F2α- isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma
Br J Ophthalmol
Ocular effects of two different prostaglandin F2α esters. A doublemasked cross-over study on normotensive eyes
Acta Ophthalmol
PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers
Arch Ophthalmol
Effects of prostaglandin D2 and its analogue, BW245C, on intraocular pressure in humans
Graefes Arch Clin Exp Ophthalmol
Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes
Jpn J Ophthalmol
Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension
Arch Ophthalmol
PhXA34—a prostaglandin F2α analogue. Effect on intraocular pressure in patients with ocular hypertension
Br J Ophthalmol
Cited by (506)
Comparison of the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density: A Randomized Clinical Trial
2022, American Journal of OphthalmologyOcular drug discovery and development
2022, Handbook of Basic and Clinical Ocular Pharmacology and TherapeuticsThe American Glaucoma Society 100: Articles with Significant Impact on Clinical Glaucoma Care
2022, Ophthalmology GlaucomaProstaglandin analogues for the treatment of glaucoma: From the «wonder» drug of the ‘90s to the reality of the 21<sup>st</sup> century
2022, Archivos de la Sociedad Espanola de OftalmologiaEfficacy and tolerance of Latanoprost given as a first intention in the treatment of primitive open angle glaucoma in African melanoderm
2021, Journal Francais d'OphtalmologiePromise of latanoprost and timolol loaded combinatorial nanosheet for therapeutic applications in glaucoma
2020, Journal of King Saud University - Science
Presented in part at the Glaucoma Society of the International Congress of Ophthalmology in Quebec City, Canada, June 1994, and as a poster at the American Academy of Ophthalmology Annual Meeting, San Francisco, November 1994.
Also submitted for publication, in part, in Glaucoma Update V. Krieglstein GK, ed, Springer-Verlag Berlin Heidelberg, which has limited distribution.
Supported by a grant from Pharmacia Pharmaceuticals, Uppsala, Sweden.
Dr. Camras is a consultant to Pharmacia Ophthalmics, Uppsala, Sweden, and to Alcon Laboratories, Fort Worth, Texas. None of the authors has a proprietary interest in the development or marketing of any drug used in this study or in any competing drug.
- *
Members of the United States Latanoprost Study Group are listed in the Appendix at the end of this article.